Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene to Offer Liquid Biopsy Through America's Choice Provider Network

NEW YORK (GenomeWeb) – Trovagene announced today that it has signed an agreement to offer its circulating tumor DNA Precision Cancer Monitoring tests and services through America's Choice Provider Network (ACPN).

Under the terms of the deal, Trovagene has become a preferred provider for the network and its liquid biopsy testing services will be covered by more than 1,700 payors in North America and available under in-network coverage to 22 million individuals.

"We are pleased that ACPN has agreed to provide coverage for Trovagene's PCM full offering of ctDNA products," Matt Posard, chief commercial officer of Trovagene, said in a statement. "Our commercial plan is on track to provide national sales coverage, and ACPN is the first of several additional contracts expected this year." 

Additional terms of the arrangement were not disclosed.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.